Combination therapies with vemurafenib in BRAF v600E–mutant cancers

Dr. Chapman Describes the Side Effects of Vemurafenib

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

Expert Discusses the Safety of Vemurafenib

Study of Vemurafenib Combined With a MEK Inhibitor

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

Dr. Chapman on Vemurafenib Combination Therapies

Regulatory Approvals for Vemurafenib/Cobimetinib, Necitumumab, and Elotuzumab

IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutat...

Melanoma, dall'Italia il vemurafenib per tutto il mondo

Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma

Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma

Vemurafenib for high risk melanoma patients

How Do BRAF-Targeted Therapies for Melanoma Work?

Dr. Taylor on Ongoing Phase II Trial of Frontline Vemurafenib Combo in Hairy Cell Leukemia

Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL

Dr. Chapman Describes the Vemurafenib Clinical Trial

Dr. Tiacci on Vemurafenib in Combination With Rituximab in HCL

MOA Animation: Melanoma BRAF Inhibition